Pila Pharma AB (publ) (PILA.ST)
SEK 2.7
(-5.44%)
SEK 2.7
(-5.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.46 Million SEK | 40.2% |
| 2022 | -8.88 Million SEK | -1405.42% |
| 2021 | 680.93 Thousand SEK | 238.29% |
| 2020 | -492.39 Thousand SEK | 76.35% |
| 2019 | -2.08 Million SEK | 28.96% |
| 2018 | -2.93 Million SEK | -38804.73% |
| 2017 | -7533.00 SEK | 98.02% |
| 2016 | -379.88 Thousand SEK | 42.49% |
| 2015 | -660.56 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -1.46 Million SEK | 0.0% |
| 2024 Q1 | -1.46 Million SEK | -45.67% |
| 2023 Q2 | -1.75 Million SEK | 4.72% |
| 2023 Q4 | -1 Million SEK | -273.23% |
| 2023 Q1 | -1.84 Million SEK | -10.53% |
| 2023 Q3 | -269 Thousand SEK | 84.69% |
| 2023 FY | -5.31 Million SEK | 40.2% |
| 2022 Q4 | -1.66 Million SEK | 12.84% |
| 2022 Q2 | -2.24 Million SEK | -891.9% |
| 2022 FY | -8.88 Million SEK | -1405.42% |
| 2022 Q1 | 284 Thousand SEK | -59.88% |
| 2022 Q3 | -1.91 Million SEK | 14.9% |
| 2021 Q1 | -27 Thousand SEK | -6787.76% |
| 2021 FY | 680.93 Thousand SEK | 238.29% |
| 2021 Q4 | 707.93 Thousand SEK | 14258.78% |
| 2021 Q3 | -5000.00 SEK | 0.0% |
| 2021 Q2 | -5000.00 SEK | 81.48% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 FY | -492.39 Thousand SEK | 76.35% |
| 2020 Q4 | -392.00 SEK | 0.0% |
| 2019 FY | -2.08 Million SEK | 28.96% |
| 2018 FY | -2.93 Million SEK | -38804.73% |
| 2017 FY | -7533.00 SEK | 98.02% |
| 2016 FY | -379.88 Thousand SEK | 42.49% |
| 2015 FY | -660.56 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Simris Alg AB (publ) | 2 Million SEK | 27.104% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 142.766% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 95.866% |
| Xintela AB (publ) | 78 Thousand SEK | -1775.667% |
| Active Biotech AB (publ) | -1.67 Million SEK | 187.344% |
| Amniotics AB (publ) | -1.93 Million SEK | 175.804% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 445.868% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.578% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.871% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.907% |
| Cantargia AB (publ) | -3.45 Million SEK | 142.394% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 11.76% |
| CombiGene AB (publ) | -21.29 Million SEK | 106.872% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 140.866% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 86.959% |
| Genovis AB (publ.) | 54 Million SEK | 97.291% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 9853.467% |
| Mendus AB (publ) | 28.48 Million SEK | 94.864% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 104.251% |
| Intervacc AB (publ) | -13.79 Million SEK | 110.606% |
| Kancera AB (publ) | -1.96 Million SEK | 174.454% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 47.88% |
| LIDDS AB (publ) | -12.92 Million SEK | 111.322% |
| Lipum AB (publ) | 53 Thousand SEK | -2660.415% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 128.591% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 85.315% |
| NextCell Pharma AB | -43.74 Million SEK | 103.344% |
| OncoZenge AB (publ) | 3000.00 SEK | -48667.333% |
| Saniona AB (publ) | 11.78 Million SEK | 87.582% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 115.913% |
| Ziccum AB (publ) | -23.28 Million SEK | 106.283% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 100.91% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 96.499% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 32.611% |
| Corline Biomedical AB | 28.38 Million SEK | 94.845% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 101.192% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 94.545% |
| Aptahem AB (publ) | 2.63 Million SEK | 44.386% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1800.026% |
| Fluicell AB (publ) | 1.73 Million SEK | 15.822% |
| Biovica International AB (publ) | 6.87 Million SEK | 78.726% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 106.284% |
| AcouSort AB (publ) | 8.38 Million SEK | 82.56% |
| Abliva AB (publ) | -35.66 Million SEK | 104.102% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 100.996% |
| 2cureX AB (publ) | -37.48 Million SEK | 103.903% |
| I-Tech AB | 27.56 Million SEK | 94.693% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 97.938% |
| Cyxone AB (publ) | 2.61 Million SEK | 43.967% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 57.008% |
| Biosergen AB | -456 Thousand SEK | 420.838% |
| Nanologica AB (publ) | -76 Thousand SEK | 2025.026% |
| SynAct Pharma AB | -778 Thousand SEK | 288.049% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 858.041% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.953% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | 92.639% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 95.97% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 239.468% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 53.303% |